Combination therapy using the complementary mechanisms of action of basal insulin and GLP-1 RA targets seven of the many pathophysiologic defects in type 2 diabetes, adressing both FPG and PPG [5, 8, 12]. This evidence concerns the gene GCG and type 2 diabetes mellitus.